SIGA Technologies Inc.
Novel anti-infectives for biological warfare defense and emerging disease threats.
SIGA designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGA’s leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including smallpox. Additional programs target arenaviruses such as Lassa fever, filoviruses such as Ebola and Marburg, flaviviruses such as Dengue fever, and other category A diseases. The company has developed a proprietary discovery platform that can be applied to many pathogens. With strong working relationships with the National Institutes of Health (NIH), the Department of Defense, and other federal agencies, SIGA believes it is competitive with all other biodefense drug development companies today. |
|
SIGA:
Tel. 212.672.9100
Fax. 212.697.3130
Email
SIGA LABS -
4575 SW Research Way, Suite 230
Tel. 541.753.2000
Fax. 541.753.9999
Email
INVESTOR RELATIONS:
KCSA Strategic Communications
Todd Fromer/Marybeth Csaby/David Burke
212-896-1215/1236/1258
Thomas N. Konatich
Vice President/CFO
SIGA
Tel. 212.672.9100
Fax. 212.697.3130
Email
MEDIA RELATIONS:
SIGA
Tel. 212.672.9100
Fax. 212.697.3130
Email
- 29 Jun 2009 : SIGA Reaches Next Stage in BARDA's RFP Bidding Process
- 26 Jun 2009 : SIGA Technologies, Inc. to be Added to the Russell 3000® and Russell Global® Indices
- 15 Jun 2009 : SIGA Completes Nonclinical Toxicology Studies Supporting Safety in Humans for ST-246®
- 09 Jun 2009 : SIGA Proposal to Fund Work on Broad Spectrum Antiviral Selected for Award by Department of Defense
- 14 May 2009 : SIGA Technologies Submits Response to BARDA RFP